About DnaJ homolog subfamily A member 2
DnaJ homolog subfamily A member 2 (DNAJA2) is a protein
from Homo sapiens identified by UniProt accession
O60884, 412 residues long.
MolForge cross-references it against 0 known binders and
50 disease associations.
Target properties
| Protein name | DnaJ homolog subfamily A member 2 |
| UniProt accession | O60884 |
| Gene | DNAJA2 |
| Organism | Homo sapiens |
| Length | 412 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (50)
Diseases linked to this target (Open Targets).
- response to simvastatin · score 0.17
- total cholesterol change measurement · score 0.17
- response to fenofibrate · score 0.17
- Female infertility due to fertilization defect · score 0.07
- neoplasm · score 0.06
- female infertility due to oocyte meiotic arrest · score 0.06
- Red cell distribution width · score 0.06
- Hydatidiform Mole · score 0.05
- cancer · score 0.05
- premature ovarian failure 19 · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60884-F1 | alphafold | PREDICTED | 83.37 | — |
Amino-acid sequence (412 residues)
MANVADTKLY DILGVPPGAS ENELKKAYRK LAKEYHPDKN PNAGDKFKEI SFAYEVLSNP EKRELYDRYG EQGLREGSGG GGGMDDIFSH IFGGGLFGFM GNQSRSRNGR RRGEDMMHPL KVSLEDLYNG KTTKLQLSKN VLCSACSGQG GKSGAVQKCS ACRGRGVRIM IRQLAPGMVQ QMQSVCSDCN GEGEVINEKD RCKKCEGKKV IKEVKILEVH VDKGMKHGQR ITFTGEADQA PGVEPGDIVL LLQEKEHEVF QRDGNDLHMT YKIGLVEALC GFQFTFKHLD GRQIVVKYPP GKVIEPGCVR VVRGEGMPQY RNPFEKGDLY IKFDVQFPEN NWINPDKLSE LEDLLPSRPE VPNIIGETEE VELQEFDSTR GSGGGQRREA YNDSSDEESS SHHGPGVQCA HQ
Explore DnaJ homolog subfamily A member 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets